University of California San Francisco
Helen Diller Family Comprehensive Cancer Center

Breast Oncology Program Seminar

October 11, 2017, 8:30 am – 10:00 am

Mount Zion
2340 Sutter Street
Lurie Seminar Room
San Francisco, CA

Sherene Loi, MDDB, PhD; Peter MacCallum Cancer Center, Victoria Australia   >view speaker profile

Title: Immunotherapeutic approaches in breast cancer.
Abstract: Checkpoint blockade has been evaluated successfully in the classically immunogenic solid tumor types such as melanoma and renal cell carcinoma, as well as in haematological malignancies. Whilst a large degree of T cell infiltrate has been observed in primary breast cancers, particularly triple negative and Her2-positive subtypes, efficacy with checkpoint blockade as monotherapy has been modest so far in studies in advanced disease. Data currently supports that line of therapy in the advanced breast cancer setting, tumor burden and T cell infiltrate predicts for higher response rates to PD-1 blockade as monotherapy. We have also observed lower levels of immune infiltrate in samples from metastatic breast cancer lesions suggesting that the primary disease setting may be the most amendable to checkpoint inhibitor approaches.
Given that most patients with advanced breast cancer have a “non-inflammed” tumor microenvironment, my lab has been evaluating how certain can modulate the immune microenvironment. Certain agents such as MEK inhibitors as well as combination targeted therapies can potentially increase tumor immunogenicity as well as synergize well with immunotherapies. These combinatorial approaches may serve to increase the response rate of immunotherapy in breast cancer patients as well as prolong duration of response in patients treated with new therapeutic agents.

Contact Information


More Information

See more events